AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) CEO Daniel Faga sold 17,679 shares of the firm's stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the completion of the transaction, the chief executive officer directly owned 495,965 shares in the company, valued at approximately $30,556,403.65. The trade was a 3.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Daniel Faga also recently made the following trade(s):
- On Thursday, January 8th, Daniel Faga sold 14,281 shares of AnaptysBio stock. The shares were sold at an average price of $44.71, for a total transaction of $638,503.51.
- On Wednesday, January 7th, Daniel Faga sold 9,202 shares of AnaptysBio stock. The stock was sold at an average price of $45.11, for a total transaction of $415,102.22.
- On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total transaction of $662,267.34.
AnaptysBio Price Performance
Shares of ANAB stock opened at $57.40 on Friday. AnaptysBio, Inc. has a 1 year low of $15.40 and a 1 year high of $68.39. The firm has a fifty day moving average price of $55.30 and a 200-day moving average price of $43.49. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -110.38 and a beta of 0.32.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.69. The company had revenue of $108.25 million for the quarter, compared to analysts' expectations of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. Equities research analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current year.
AnaptysBio announced that its Board of Directors has approved a share repurchase program on Friday, March 27th that authorizes the company to repurchase $100,000.00 billion in shares. This repurchase authorization authorizes the biotechnology company to buy up to 5,352,316.2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's leadership believes its stock is undervalued.
Hedge Funds Weigh In On AnaptysBio
A number of hedge funds have recently made changes to their positions in ANAB. Smartleaf Asset Management LLC grew its position in shares of AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 821 shares in the last quarter. Larson Financial Group LLC raised its stake in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 473 shares during the period. Bessemer Group Inc. lifted its holdings in AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 1,377 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its stake in AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 2,326 shares during the period.
Wall Street Analysts Forecast Growth
ANAB has been the topic of a number of analyst reports. HC Wainwright lifted their price objective on AnaptysBio from $51.00 to $66.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Truist Financial raised shares of AnaptysBio to a "hold" rating in a report on Wednesday. UBS Group raised their target price on shares of AnaptysBio from $70.00 to $90.00 and gave the stock a "buy" rating in a research note on Tuesday, March 17th. Guggenheim reaffirmed a "buy" rating on shares of AnaptysBio in a report on Thursday, December 18th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of AnaptysBio in a research report on Wednesday, January 21st. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $78.44.
Check Out Our Latest Analysis on ANAB
About AnaptysBio
(
Get Free Report)
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
